Holen Sie sich die Stockscreener-App
23.66
1.81%
0.29
Schlusskurs vom Vortag:
$23.37
Offen:
$23.56
24-Stunden-Volumen:
125.36K
Relative Volume:
0.21
Marktkapitalisierung:
$769.29M
Einnahmen:
$796.33M
Nettoeinkommen (Verlust:
$74.95M
KGV:
11.58
EPS:
2.0427
Netto-Cashflow:
$329.83M
1W Leistung:
-2.09%
1M Leistung:
-19.26%
6M Leistung:
-36.16%
1J Leistung:
-37.34%
1-Tages-Spanne:
$23.31
$23.84
1-Wochen-Bereich:
$23.11
$24.43
52-Wochen-Spanne:
$23.11
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Firmenname
Collegium Pharmaceutical Inc
Sektor
Telefon
781-713-3699
Adresse
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
23.63 | 760.82M | 796.33M | 74.95M | 329.83M | 2.0427 |
TAK
Takeda Pharmaceutical Co Adr
|
18.31 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.85 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.155 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.48 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
496.69 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-01-10 | Hochstufung | Needham | Hold → Buy |
| 2024-07-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-05-10 | Herabstufung | Needham | Buy → Hold |
| 2024-05-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-25 | Bestätigt | Needham | Buy |
| 2023-05-02 | Fortgesetzt | Jefferies | Buy |
| 2022-08-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-14 | Eingeleitet | BWS Financial | Sell |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-19 | Fortgesetzt | Jefferies | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2019-04-12 | Fortgesetzt | Janney | Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2018-02-07 | Bestätigt | Needham | Buy |
| 2017-12-05 | Bestätigt | Needham | Buy |
| 2017-09-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-09-13 | Eingeleitet | Gabelli & Co | Buy |
| 2015-06-01 | Eingeleitet | Jefferies | Buy |
| 2015-06-01 | Eingeleitet | Needham | Buy |
| 2015-06-01 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
Collegium to Participate in Upcoming Investor Conferences - GlobeNewswire
Collegium Pharmaceutical stock edges higher after recent quarterly update - AD HOC NEWS
Collegium Pharmaceutical Inc. (COLL) Peer Comparison – Compare with Others - Value Research
(COLL) Risk Channels and Responsive Allocation - Stock Traders Daily
A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39 - GuruFocus
Israel A. Englander reports new Collegium (NASDAQ: COLL) stake - Stock Titan
Collegium (COLL) Move: Ends Higher by 2.18% at $27.70 in Latest Trading; Technical View: the $26.31 to $29.09 Range Remains in Focus in the Latest SessionETF NAV Deviation - vinanet.vn
Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Cuts Target Price to $48 - Moomoo
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call - Yahoo Finance
Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock - Stock Titan
Collegium Pharmaceutical stock jumps on $50M share buyback - Investing.com
COLLEGIUM PHARMACEUTICAL INC : NEEDHAM CUTS TARGET PRICE TO $46 FROM $56 - webull.com
Can Collegium Pharmaceutical (NASDAQ:COLL) Rebound From Its Yearly Low? - Kalkine Media
Collegium Pharmaceutical Initiates $50 Million Accelerated Share Buyback with Jefferies LLC - Kalkine Media
Collegium Pharmaceutical stock jumps on $50M share buyback By Investing.com - Investing.com Canada
Why is Collegium Pharmaceutical stock climbing today? By Investing.com - Investing.com Canada
Collegium Pharmaceutical Launches $50 Million Accelerated Share Repurchase Program - citybiz.co
Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Collegium Pharmaceutical to repurchase $50 million in stock By Investing.com - Investing.com Nigeria
Collegium gains on accelerated share buybacks (COLL:NASDAQ) - Seeking Alpha
Collegium Pharmaceutical to repurchase $50 million in stock - Investing.com
Collegium Pharmaceutical launches $50M accelerated share repurchase under $150M buyback program - TradingView
Collegium Announces $50 Million Accelerated Share Repurchase Program - GlobeNewswire
Collegium Pharmaceutical (NASDAQ:COLL) Sets New 1-Year LowTime to Sell? - MarketBeat
Collegium Pharmaceutical Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Collegium Pharmaceutical (COLL) Slips 0.85% While Holding Above Key Support at $25.62Breakout Trade - vinanet.vn
Collegium Pharmaceutical (NASDAQ:COLL) Shares Down 6.5%Here's What Happened - MarketBeat
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance - Yahoo Finance
Collegium Pharmaceutical, Inc. Revenue Breakdown – NASDAQ:COLL - TradingView
Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze - simplywall.st
Collegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at Wall Street Zen - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Releases Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Piper Sandler Maintains Collegium Pharmaceutical(COLL.US) With Hold Rating, Cuts Target Price to $43 - Moomoo
Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return - simplywall.st
Piper Sandler Reiterates Neutral Rating for Collegium Pharmaceutical (NASDAQ:COLL) - MarketBeat
Is Now The Time To Put Collegium Pharmaceutical (NASDAQ:COLL) On Your Watchlist? - Moomoo
Collegium Pharmaceutical, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:COLL) 2026-08-07 - Seeking Alpha
Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Unveiling an 82.76% Potential Upside - DirectorsTalk Interviews
Collegium Pharmaceutical (NASDAQ:COLL) Hits New 1-Year Low Following Analyst Downgrade - MarketBeat
Collegium Pharmaceutical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Collegium Pharmaceutical stock hits 52-week low at 30.11 USD - Investing.com
Collegium Pharmaceutical, Inc. Stock 12‑Month Price Target Cut to $51.2, Implies 43% Upside - TradingView
Needham & Company LLC Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $46.00 - MarketBeat
Collegium Pharmaceutical Releases Q2 2026 Financial Results - AlphaStreet
Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap DownShould You Sell? - MarketBeat
Collegium Pharmaceutical Down Over 13%, On Track for Largest Percent Decrease Since May 2024 -- Data Talk - Moomoo
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Collegium Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Collegium Pharmaceutical Q2 Earnings Call Highlights - MarketBeat
Collegium Pharmaceutical falls 13% on weak revenue guidance By Investing.com - Investing.com South Africa
Finanzdaten der Collegium Pharmaceutical Inc-Aktie (COLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):